Market Scenario:
The adrenal glands within the body produce some essential hormones like aldosterone. This hormone balances the levels of sodium and potassium in the blood. Primary aldosteronism is a medical condition in which the adrenal glands produce high levels of aldosterone, causing the patient to lose potassium and retain sodium. This excess levels of sodium, increases the blood volume and blood pressure. The diagnosis and treatment of primary aldosteronism is important because it increases the risk of the heart diseases and stroke. This has provided the essential background for market growth. Factors such as increasing prevalence of primary aldosteronism and the growing geriatric population are the major drivers for the market growth. According to a study published in the International Journal of Endocrinology and Metabolism in 2016, the prevalence of the primary aldosteronism was estimated to be greater than 5%. Moreover, increasing obese population and rising consumption of alcohol is estimated to fuel the market. According to the World Health Organization, in 2016, approximately 1.9 billion adults aged 18 years or more were overweight. Moreover, it was estimated that out this population more than 650 million were obese. Additionally, rising per capita healthcare expenditure boosts the market growth. However, lack of awareness and risks associated with corrective surgeries like excessive bleeding, infection, anesthesia reaction besides others are estimated to restrain the market growth during the forecast period.
Reqeust for Sample Copy @ https://www.marketresearchfuture.com/sample_request/5522

The global primary aldosteronism market is expected to grow at a CAGR of 8.40% during forecast period.
Intended Audience
• Pharmaceutical companies
• Biotechnological institutes
• Government and Private Laboratories
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Market Research and Consulting Service Providers
Segmentation
The global primary aldosteronism market is segmented on the basis of type, indications, diagnosis, treatment and end users.
On the basis of type, the market is segmented as Type I, and Type II. On the basis of indications, the market is categorized into heart attack, kidney failure, stroke, and others. On the basis of diagnosis, the market is segmented into blood test, imaging, and others. The blood test segment is sub-segmented into aldosterone profiling, renin profiling, and others. The imaging segment is sub-segmented into computed tomography (CT), positron emission tomography (PET), and others.On the basis of end users, the market is segmented into surgery, aldosterone antagonists, and others. The aldosterone antagonists is sub-m segmented into spironolactone, eplerenone, and others.
Regional Analysis
America dominates the global primary aldosteronism market owing to a well-developed healthcare sector and a huge patient population. Apart from this, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Population Reference Bureau, the American geriatric population is projected to double and reach approximately over 98 million by 2060.
Europe is the second largest market for primary aldosteronism, and is followed by Asia Pacific. Availability of funds for research, a huge patient population and government support for research & development are the driving factors for the market within the region. On a regional basis, the market is segmented into Western Europe, and Eastern Europe. The Western Europe leads the market due to the presence of developed economies like Germany, Italy, France, and others. On the other hand, Eastern Europe is estimated to be the fastest growing market.
Asia Pacific is projected to be the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China. According to the Indian Brand Equity Foundation, the Indian healthcare sector is estimated to be one of the fastest growing sectors and is projected to advance at an estimated CAGR of 22.87% from 2015 to 2020 and reach USD 280 billion till 2020.
On the other hand, the Middle East & Africa has the least share in the global primary aldosteronism market due to the presence of weak economies, stringent government policies and lack of healthcare services especially within the African region. A majority of the market within the Middle East and Africa is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure in the region.
Request Full Report @ https://www.marketresearchfuture.com/reports/primary-aldosteronism-market-5522

Key players for global primary Aldosteronism market
The key players for the global primary aldosteronism market are Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol Laboratories Ltd (England), CMP Pharma. (U.S.), Koninklijke Philips N.V. (The Netherlands), GE Healthcare (U.K), Siemens AG (Germany), Shimadzu Corporation (Japan), Canon Inc. (Japan), and others.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312l
Email: [email protected]